Answers are grounded in this paper and cite their sources.
Preprint reveals a unified mRNA-LNP platform for cone photoreceptor rescue in retinitis pigmentosa, indicating a potential broad application.
This preprint presents the ORION SHIELD platform, a unified gene-agnostic, re-dosable mRNA-LNP therapeutic framework for cone photoreceptor rescue in retinitis pigmentosa (RP). The platform integrates three mechanistically complementary axes: SHIELD-α (anti-HMGB1 nanobody mRNA + P2X7R antagonism for DAMP neutralization), SHIELD-β (IL-10 + TGF-β1 mRNA in hyaluronic acid-modified LNPs for microglial M1-to-M2 repolarization), and SHIELD-γ (MCT2 + Txnip mRNA with circadian-synchronized dosing for RPE-cone metabolic restoration). Each axis is grounded in published preclinical evidence; none has been previously assembled into a unified RP therapeutic. The platform addresses approximately 95% of the global RP patient population either as monotherapy or as adjunct to existing gene-specific therapies. Includes integration with ORION-QUBO quantum-assisted payload optimization and Digital Dr. clinical monitoring system. Includes complete 36-month development roadmap to first-in-human Phase 1/2 trial. Companion preprints SHIELD-α, SHIELD-β, and SHIELD-γ are included in the same Zenodo record.
No takes yet. Share an insight, caveat, or question.
Omar Rafael Pérez Gallardo (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: